NOVABAY PHARMACEUTICALS INC (NBY) Fundamental Analysis & Valuation
NYSEARCA:NBY • US66987P4090
1.21 USD
-0.06 (-4.72%)
At close: Mar 13, 2026
1.22 USD
+0.01 (+0.83%)
After Hours: 3/13/2026, 4:39:38 PM
This NBY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall NBY gets a fundamental rating of 2 out of 10. We evaluated NBY against 193 industry peers in the Pharmaceuticals industry. NBY has a bad profitability rating. Also its financial health evaluation is rather negative. NBY is quite expensive at the moment. It does show a decent growth rate.
1. NBY Profitability Analysis
1.1 Basic Checks
- In the past year NBY has reported negative net income.
- In the past year NBY has reported a negative cash flow from operations.
- In the past 5 years NBY always reported negative net income.
- NBY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- NBY's Return On Assets of -251.48% is on the low side compared to the rest of the industry. NBY is outperformed by 88.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NBY has a Gross Margin of 66.26%. This is in the better half of the industry: NBY outperforms 75.13% of its industry peers.
- In the last couple of years the Gross Margin of NBY has declined.
- NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
2. NBY Health Analysis
2.1 Basic Checks
- NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NBY has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for NBY has been increased compared to 5 years ago.
- Compared to 1 year ago, NBY has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -71.69, we must say that NBY is in the distress zone and has some risk of bankruptcy.
- NBY has a worse Altman-Z score (-71.69) than 92.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -71.69 |
ROIC/WACCN/A
WACC9.65%
2.3 Liquidity
- NBY has a Current Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
- NBY's Current ratio of 0.68 is on the low side compared to the rest of the industry. NBY is outperformed by 89.12% of its industry peers.
- NBY has a Quick Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
- NBY's Quick ratio of 0.41 is on the low side compared to the rest of the industry. NBY is outperformed by 89.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 |
3. NBY Growth Analysis
3.1 Past
- NBY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.82%, which is quite impressive.
- Looking at the last year, NBY shows a very negative growth in Revenue. The Revenue has decreased by -33.58% in the last year.
- NBY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.19% yearly.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
3.2 Future
- Based on estimates for the next years, NBY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.55% on average per year.
- NBY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.46% yearly.
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. NBY Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.
- Also next year NBY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NBY's earnings are expected to grow with 31.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A
5. NBY Dividend Analysis
5.1 Amount
- NBY has a Yearly Dividend Yield of 57.55%, which is a nice return.
- In the last 3 months the price of NBY has falen by -90.93%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 0.71, NBY pays a better dividend. On top of this NBY pays more dividend than 100.00% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, NBY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 57.55% |
5.2 History
- NBY is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y31.55%
EPS Next 3YN/A
NBY Fundamentals: All Metrics, Ratios and Statistics
1.21
-0.06 (-4.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-31 2026-03-31/amc
Inst Owners5.45%
Inst Owner Change1891.11%
Ins Owners4.89%
Ins Owner Change0%
Market Cap31.61M
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio1.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 57.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.37
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% | ||
| FCFM | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -71.69 |
F-Score4
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A
NOVABAY PHARMACEUTICALS INC / NBY FAQ
Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 2 / 10 to NBY.
Can you provide the valuation status for NOVABAY PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.
Can you provide the profitability details for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.
What is the expected EPS growth for NOVABAY PHARMACEUTICALS INC (NBY) stock?
The Earnings per Share (EPS) of NOVABAY PHARMACEUTICALS INC (NBY) is expected to grow by 39.01% in the next year.